kyv-101
kyv-101: developed by 1 company · 5 clinical trials tracked.
kyv-101 evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could kyv-101 → KYTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Kyverna Therapeutics, Inc. (KYTX) Refractory Lupus Nephritis; Myasthenia Gravis; Systemic Scle… | Phase 1/Phase 2 |
Clinical Trials (5)
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Primary endpoint: Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU).
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis. Two-stage Interventional, Prospective, Randomized, Controlled, Open Label, Parallel-group Phase I/II Trial in Patients With Active, ACPA-positive and Treatment Refractory Rheumatoid Arthritis
Primary endpoint: Safety Phase I (1) Safety
KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis
Primary endpoint: Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2)
KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Primary endpoint: Incidence of adverse events and laboratory abnormalities (Phase 1)
CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)
Primary endpoint: Incidence and severity of AEs in IIM.
Frequently asked questions
Who is developing kyv-101?
kyv-101 is being developed by Kyverna Therapeutics, Inc..
How many clinical trials involve kyv-101?
BioSniper tracks 5 clinical trials involving kyv-101.